U.S. Markets closed

Seattle Genetics, Inc. (SGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
65.57-0.45 (-0.68%)
At close: 4:00PM EDT
People also watch
  • Are we up because of the abstracts at ASCO?
  • I'll buy more at $60
  • Why are we down so much today? Any news?
  • Baker Bothers just bought more shares of SGEN at $66.60 per share.
  • Marriage is the triumph of imagination over intelligence. http://dataunion.tistory.com/3192

    Seattle Genetics NASDAQ : SGEN Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.5 In other words, the correlation coefficient of the other stock
  • ASG-22: Three (3) complete responses so far at the high dose range. Ricardo is impressed.
  • Clay, the CEO, just unloaded another chunk. Must be nice. I'd buy a Rolex Cosmograph for all my friends with the proceeds and then maybe a Maserati
  • Finally some common sense clarity on the IMMU expedition. Wish them well and hope that the door doesn not slam on they backside on the way out. Let's see how VenBios finances IMMU 132 trials now and how experienced they are at convincing the FDA for an early conditional approval based on the very limited PII data that they have on hand and are afraid to present at ASCO for the second time. Only beef I have with SGEN is that they did not take profit on the original investment while they had it. Maybe they could not by covenant. I doubt that they get a better deal from a new partner when 30% OF PIII's fail in spite of good PII results.
  • I sold some in my Roth IRA at 69 and bought it back under 60. It's up a few bucks. Hope it hits
    65+ this week
  • Why the big drop????
  • so when do we stop bleeding?
  • It is clear from the current neutral insider ownership of 0.90% that SGEN could yield both a pullback or an uptick. The scenarios are quite interesting at current levels. if you guys have questions you should ask a.awesomestocks. They often respond to my emails which is helpful.
  • Two things that might be easy to miss in the just-released 1Q report (in which revenues beat and earnings/losses were in-line):

    1. The last sentence in this paragraph: "Royalty revenues of $17.0 million, compared to $32.3 million in the first quarter of 2016. Royalty revenues are primarily driven by international sales of ADCETRIS by Takeda. Royalty revenues in the first quarter of 2016 included a $20.0 million sales milestone payment from Takeda."

    2. And this, meaning we'll see the revenue in Q2 results: "ADC Collaborations: In April 2017, Seattle Genetics generated a milestone under its ongoing ADC collaboration with AbbVie triggered by AbbVie’s exercise of an exclusive option to Seattle Genetics’ ADC technology for a specific target antigen."
  • We look to be setting up for a nice move...it's been a while but we're about due to make a new high...and, as the previous poster opines, going right to $75...In actuality, I think we're ready to get over that hurdle.

    The screwing around with IMMU has been "fun" to watch and it'll be interesting to see if SGEN and IMMU can make something work...though I think the other side and venBio are trying to wrangle something else.
  • Smart post Yahoo Reader. You hit the nail on the head about trading this stock.
  • Clay's response on the $IMMU deal.

    "Yeah. Sure. The IMMU deal, right now it's a legal issue and so we're not providing any specific updates. As you know the facts are that there was a temporary restraining order or TRO, and the fact is that there is a trial listed in late June. But please keep in mind that when we think about it IMMU-132, this was something that we thought fit in and we thought would be nice to have with the rest of our very extensive pipeline. But it is certainly not something that is needed. We have many programs that we're focused on and pushing forward hard on, but otherwise to answer to your question, it's a legal issue and it's not appropriate to make comment."
  • Revenues were good. I don't see any after-hours pricing.
  • When this #$%$ breaks $70, it's going right to 75
  • Nice pop today. 🤑
  • The judge ordered 30 day delay in the IMMU saga was over yesterday but not a peep. Wish they would just walk away from this deal. $300 million upfront for a PII drug that may garner conditional FDA approval is a pretty good deal for the cash strapped IMMU shareholder and a price that no one else is apparently willing to even match in spite of what I now two additional months of going shopping. I think the evidence supports SGEN reconsidering the deal and scaling back at least the upfront payment if not completely walk away and let VenBio deal with the fallout.